Rationale for the development and current status of calcitriol in androgen-independent prostate cancer

World Journal of Urology

Volumn 23, Issue 1, 2005, Pages 28-32

  Beer, Tomasz M ^a   Myrthue, Anne ^a   Eilers, Kristine M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Calcitriol; Prostate cancer; Vitamin D

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CALCITRIOL; CYTOTOXIC AGENT; DEXAMETHASONE; DN 101; DOCETAXEL; MITOXANTRONE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER TISSUE; CELL CYCLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; HORMONE DEPENDENCE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MALE; PROSTATE CANCER; SIDE EFFECT; TISSUE TYPES; TUMOR VASCULARIZATION;

ANDROGENS; ANIMALS; APOPTOSIS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 15844421214     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0476-y     Document Type: Article

References (54)

1. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T (1981) Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 78:4990-4994 v7fg8
2. Ahmed S, Johnson CS, Rueger RM, Trump DL (2002) Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/ dexamethasone in an androgen independent prostate cancer model. J Urol 168:756-761
3. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD (2001) Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28 [Suppl 15]:49-55
4. Beer TM, Munar M, Henner WDA (2001) Phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation. Cancer 91:2431-2439
5. Beer TM, Pierce WC, Lowe BA, Henner WD Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279
6. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128
7. Beer TM, Lemmon D, Lowe BA, Henner WD (2003) High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97:1217-1224
8. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC (1988) Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67:607-613
9. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS (2001) Combination of 1alpha, 25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7:4164-4173
10. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL (2002) Antiproliferative effects of 1alpha, 25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-2514
11. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28[Suppl 15]:8-15
12. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997) Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15-27
13. Campbell MJ, Koeffler HP (1997) Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 89:182-185
14. Drivdahl RH, Loop SM, Andress DL, Ostenson RC (1995) IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 26:72-79
15. Fan FS, Yu WC (1995) 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 13:280-286
16. Friedland D, Cohen J, Miller RJr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B (1999) A phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 [Suppl 17]:19-23
17. Galbiati F, Polastri L, Thorens B, Dupraz P, Fiorina P, Cavallaro U, Christofori G, Davalli AM (2003) Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology 144:1832-1841
18. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006
19. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)J Urol 159 2035-2040
20. Guzey M, Kitada S, Reed JC (2002) Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1:667-677
21. Hedlund TE, Moffatt KA, Miller GJ (1996) Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-288
22. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644-2649
23. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL (2001) Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043-1051
24. Holick MF (2003) Vitamin D: A millenium perspective. J Cell Biochem 88 296-307
25. James SY, Mackay AG, Colston KW (1996) Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 58:395-401
26. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001) Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370-1380
27. Kobayashi T, Hashimoto K, Yoshikawa K (1993) Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 196:487-493
28. Koli K, Keski-Oja J (2000) 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 11:221-229
29. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
30. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S (1996) Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1:97-101
31. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. (1995) The nuclear receptor superfamily: The second decade. Cell 83:835-839 10.1016/ 0092-8674(95)90199-X
32. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214-220
33. Modzelewski RA, Hershberger PA, Johnson CS, Trump DL (1999) Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumors in vitro. Proc Am Assoc Cancer Res 40:580
34. Moffatt KA, Johannes WU, Miller GJ (1999) 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695-703
35. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL (2002) Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72:648-659
36. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195-198
37. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D (1994) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
38. Peng L, Malloy PJ, Feldman D (2004) Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109-1119
39. Pepper C, Thomas A, Hoy T, Milligan D, Bentley P, Fegan C (2003) The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 101:2454-2460
40. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26 [Suppl 17]:14-18
41. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL (2003) p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144:50-60
42. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR (1994) Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081
43. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 Alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-732
44. Sheikh MS, Rochefort H, Garcia M (1995) Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11:1899-1905
45. Skowronski RJ, Peehl DM, Feldman D (1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
46. Skowronski RJ, Peehl DM, Feldman D (1995) Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136:20-26
47. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL (1999) A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5:1339-1345
48. Sung V, Feldman D (2000) 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164:133-143
49. Wang QM, Jones JB, Studzinski GP (1996) Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264-267
50. Yen A, Varvayanis S (1994) Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp Cell Res 214:250-257
51. Yu WD, McElwain MC, Modzelewski RA, Russell D M, Smith DC, Trump DL, Johnson CS (1998) Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 90:134-141
52. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL (1997) Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90
53. Zhuang SH, Burnstein KL (1998) Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-1207
54. Zittermann A (2003) Vitamin D in preventive medicine: Are we ignoring the evidence? Br J Nutr 89:552-572 10.1079/BJN2003837